This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

RT-MediBus© Announces Integration With MacPractice PMS

The RT-MediBus UbiKare iPad app is currently available on the Apple Store. The app permits physicians to view real time vitals and clinical notes and e-prescribe. In late February RT-MediBus will release UbiKare 2 ©, which will enable clinical note taking on the iPad and help to revolutionize EHR adoption.

"Ease of use has been a major impediment to EHR adoptions. Many physicians find it time consuming and distracting to enter data when they see patients. Furthermore, customizing templates to each physician's specific needs has not been that easy or inexpensive in most EHR systems," said RT-MediBus CEO Sethu Nambiar. "RT-MediBus's UbiKare 2 app for iPad will not only let a physician record clinical data during a patient visit easily, but also enable them to do so without increasing time spent, changing their work style or having to learn new skills."

During MacWorld/iWorld, January 31-February 2, 2013, RT-MediBus is demonstrating a beta version of its UbiKare 2 in the MacPractice Booth 205, Moscone Center West.

About RTMediBus: RT-MediBus © is a cloud based EHR, certified as a complete ONC-ATCB EHR for ambulatory care. RT-MediBus © EHR is a business tool enabling Physicians to increase revenues by making their office and clinic more efficient while making the transition to EHR relatively easy. Visit

About MacPractice: MacPractice, Inc. is a client-centric practice management and clinical software development firm, comprising highly experienced and caring individuals, dedicated to the development and support of best-of-class Macintosh software, hardware and associated services for physicians, dentists, chiropractors and eye doctors. Visit


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs